First author | Year of publication | Time set | Study Design | Mean Age CS group | Gender Distribution (M/F) | The country | Population TMVR (CS/without CS) | Population CS group | STS score CS group | hospital length of stay Mean (SD), day | postprocedural MR ≤ 2+ | HTN CS group | CAD CS Group | LVEF CS group | mPAP CS group |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P. Kovach et al. [41] | 2021 | January 2018 and March 2019 | Retrospective Cohort | 72 ± 13 | (10/10) | USA | 20(8/12) | 8 | N. A | N. A | N. A | N. A | N. A | N. A | N. A |
Lee et al. [42] | 2021 | 2019–2021 | Cohort | 72.6 ± 18.2 | (6/34) | Taiwan | 50(8/42) | 8 | 19.7 ± 12.0 | N. A | 7 | 6 | 6 | 40.4 ± 16.8 | 40.6 ± 10.5 |
Simard et al. [46] | 2022 | November 2013 to December 2021 | Retrospective Cohort | 73.0 ± 11.9 | (1519/2278) | USA | 3797 (3797/0) | 3797 | 14.9 ± 15.3 | 12.5 ± 15.0 | 3397 | 3132 | 1488 | 41.1 ± 17.5 | N. A |
Haberman et al. [39] | 2024 | December 2009 to September 2022 | Retrospective Cohort | 68 ± 14 | (10/13) | North America & Europe and Middle East | 23(20/3) | 20 | N. A | 11.3 ± 7.98 | 13 | N. A | 15 | 45.6 ± 7.96 | N. A |
Jung et al. [40] | 2021 | January 2011 and February 2019 | Retrospective Cohort | 68.9 ± 12.1 | (78/63) | North America & Europe | 141(141/0) | 141 | 16.1 ± 16.6 | 12.0 ± 10.49 | N. A | 85 | 86 | 33.8 ± 14.0% | 36.9 ± 10.1 |
Tang et al. [49] | 2021 | January 2014 to March 2019 | Retrospective Cohort | 71 ± 11 | (257/492) | USA | 596(596/0) | 596 | N. A | 17.0 ± 11.15 | N. A | 542 | 421 | N. A | N. A |
Adamo et al. [31] | 2017 | October 2010 to October 2015 | Case series | 73 ± 6 | (2/3) | Italy | 5(4/1) | 4 | N. A | N. A | 4 | N. A | N. A | N. A | N. A |
Makmal et al. [43] | 2024 | July 2012 to March 2022 | Retrospective cohort | 73.5 ± 10.9 | (10/21) | Isreal | 31(9/22) | 9 | N. A | N. A | N. A | N. A | N. A | N. A | N. A |
Aldrugh et al. [21] | 2021 | 2010–2018 | Retrospective cohort | 73. ± 14 | (243/364) | USA | 607(607/0) | 607 | N. A | 17.33 ± 12.63 | N. A | 497 | 419 | N. A | N. A |
Estévez-Loureiro et al. [35] | 2021 | January 2016 to February 2020 | Retrospective cohort | 68 ± 10 | (48/45) | North America and Europe | 93(50/43) | 50 | N. A | N. A | 45 | 33 | N. A | 34 ± 12 | 40 ± 13 |
So et al. [47] | 2022 | Jan 2014 to December 2019 | Retrospective cohort | 70.3 ± 11.5 | 8(3/5) | USA | 8(8/0) | 8 | 31.0 ± 10.5 | N. A | 5 | N. A | N. A | 54.1 ± 8.4 | N. A |
Falasconi et al. [36] | 2021 | 2012 to 2019 | Retrospective cohort | 70.3 ± 3.8 | (4/27) | Italy and USA | 31(31/0) | 31 | 37.9 ± 8.89 | N. A | 27 | N. A | 24 | 30.0 ± 8.86 | 30.7 ± 5.67 |
Flint et al. [37] | 2019 | November 2013 to October 2018 | Retrospective cohort | 71.7 ± 12.8 | (56/79) | USA | 135(12/123) | 12 | 33.4 ± 22.3 | N. A | 12 | N. A | N. A | 37 ± 15 | 38 ± 11/33 |
Perel et al. [44] | 2022 | January 2020 to July 2021 | Retrospective cohort | 70.3 ± 10.3 | (1/12) | Isreal | 13(13/0) | 13 | N. A | 10.33 ± 13.29 | 13 | N. A | N. A | N. A | N. A |
Cheng et al. [33] | 2019 | January 2014 and August 2018 | Retrospective cohort | 65.5 ± 17.0 | (5/24) | USA | 29(29/0) | 29 | N. A | N. A | 26 | N. A | N. A | 27.3 ± 16.6 | N. A |
Rizik et al. [45] | 2019 | 2019 | Case series | 81.7 ± 10.0 | (0/3) | USA | 3(3/0) | 3 | N. A | N. A | 3 | N. A | N. A | N. A | N. A |
Garcia et al. [38] | 2020 | 2010–2019 | Retrospective cohort | 74 ± 11 | (5/6) | USA | 11(11/0) | 11 | N. A | N. A | 8 | N. A | N. A | N. A | N. A |
Chitturi et al. [34] | 2020 | Early 2020 | Case series | 58.0 ± 2.8 | (0/2) | USA | 2(2/0) | 2 | N. A | N. A | 2 | N. A | N. A | N. A | N. A |
Vandenbriele et al. [50] | 2021 | August 2017 and January 2020 | Case series | 66.8 ± 4.9 | (2/4) | USA | 6(6/0) | 6 | N. A | 17.5 ± 5.2 | 6 | N. A | N. A | N. A | N. A |
Tanaka et al. [48] | 2022 | late 2020 and early 2022 | Case series | 69 ± 2.65 | (1/2) | Japan | 3(3/0) | 3 | N. A | N. A | 3 | N. A | N. A | N. A | N. A |
Ahmed et al. [32] | 2023 | N.A | Case series | 57 ± 7.1 | (0/2) | Qatar | 2(2/0) | 2 | N. A | N. A | 2 | N. A | N. A | N. A | N. A |